Geron (NASDAQ:GERN) shareholders got some welcome news at last with the lift of the partial clinical hold on imetelstat for myelofibrosis. So is now the time to buy the stock?
Not so fast. There's still a clinical hold for polycythemia vera and multiple myeloma. And imetelstat is still in phase 2 trials -- so commercialization is still some ways away. It's not that the stock is necessarily a bad investment -- it's that there's still too much uncertainty to be sure that it's a good investment.
In the video below, from Market Checkup, health care analysts Michael Douglass and David Williamson lay out why Foolish investors should still avoid Geron's stock.
Leaked: This coming blockbuster will make every biotech jealous
The best biotech investors consistently reap gigantic profits by recognizing true potential earlier and more accurately than anyone else. Let me cut right to the chase. There is a product in development that will revolutionize not how we treat a common chronic illness, but potentially the entire health industry. Analysts are already licking their chops at the sales potential. In order to outsmart Wall Street and realize multi-bagger returns you will need to Motley Fool's new free report on the dream-team responsible for this game-changing blockbuster. CLICK HERE NOW.
David Williamson has no position in any stocks mentioned. Michael Douglass has no position in any stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.